| Identification | Back Directory | [Name]
3(2H)-Pyridazinone, 4-chloro-5-[4-[4-fluoro-2-(trifluoromethyl)phenoxy]-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]- | [CAS]
2413739-88-3 | [Synonyms]
Evifacotrep
5-chloro-4-[4-[4-fluoro-2-(trifluoromethyl)phenoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-1H-pyridazin-6-one
3(2H)-Pyridazinone, 4-chloro-5-[4-[4-fluoro-2-(trifluoromethyl)phenoxy]-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]- | [Molecular Formula]
C18H12ClF4N5O2 | [MOL File]
2413739-88-3.mol | [Molecular Weight]
441.77 |
| Chemical Properties | Back Directory | [density ]
1?+-.0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (113.18 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
9.10±0.60(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Evifacotrep, a short transient receptor potential channel 5 and 4 (TRPC5/TRPC4) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases. Evifacotrep targets to TRPC5/TRPC4 with IC50s ≤50 nM[1]. | [in vivo]
Evifacotrep (30 mg/kg; sc; once daily or twice daily for 10 days) results in reduced urinary albumin excretion on following injury with puromycinaminonucleoside (PAN)[1]. | [storage]
Store at -20°C | [References]
[1] WO2020061162 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|